Preterm Babies Missing Critical Protective Treatments—And It Depends on Where They're Born

A major international study has uncovered a troubling reality: babies born prematurely aren't receiving two proven medications that can prevent serious complications, and the gap depends largely on which country they're born in. Researchers analyzing data from over 45,000 preterm infants found that magnesium sulfate and steroids—treatments recommended worldwide for pregnant women at risk of early delivery—are used inconsistently, leaving many vulnerable newborns without protection.

What Are These Medications, and Why Do Preterm Babies Need Them?

When a pregnancy is at risk of ending before 32 weeks, two medications can make a dramatic difference in a newborn's health. Magnesium sulfate reduces the risk of cerebral palsy, a lifelong neurological condition affecting movement and coordination. Prenatal steroids help develop the baby's lungs, reducing respiratory complications that can require intensive care or mechanical ventilation. Together, they offer what experts call "the best start in life" for babies born too early.

The problem isn't that these treatments don't work—decades of research confirm they do. The problem is that they're not being used equally around the world.

How Big Is the Treatment Gap Between Countries?

Researchers from the University of Bristol reviewed data from 2012 to 2024 covering 1,111 hospitals across an international network, combined with information from the UK National Neonatal Research Database and a comprehensive literature review. The findings were striking:

• Middle-Income Countries: Fewer than 50% of preterm infants received magnesium sulfate, leaving the majority without this cerebral palsy protection.
• High-Income Countries: Approximately 75% of preterm infants received magnesium sulfate, though this still means one in four babies missed out.
• Variation Within Countries: Even among wealthy nations, there were large discrepancies in how often these treatments were given, suggesting inconsistent hospital protocols rather than resource constraints.
• Steroid Use: Prenatal steroids were used more frequently and with less variation, but treatment gaps remained apparent across all regions.

"Our study has highlighted the international disparities in how two key treatments to protect pre-term babies are implemented. These gaps aren't because of a lack of evidence," said Hannah B. Edwards, MA, MSc, of the University of Bristol, the study's corresponding author. "Lessons can be learned from successful implementation programs like PReCePT, which has transformed use of magnesium sulphate in pre-term births in England".

Steps to Close the Global Treatment Gap

The research team identified concrete ways to improve access to these lifesaving medications:

• Learn From Success Stories: Programs like PReCePT in England have dramatically increased magnesium sulfate use by standardizing protocols and training healthcare providers, proving that change is possible even in complex healthcare systems.
• Standardize Hospital Guidelines: Hospitals should adopt clear, evidence-based protocols for administering both magnesium sulfate and steroids to all pregnant women at risk of preterm delivery, regardless of location or income level.
• Invest in Provider Education: Healthcare workers need training on when and how to administer these medications, ensuring that knowledge gaps don't prevent treatment even when resources are available.
• Monitor and Report Data: Hospitals should track their own treatment rates and compare them to international standards, creating accountability and identifying areas for improvement.

Why Does Geography Determine a Baby's Access to Protection?

The disparities revealed in this research point to systemic issues beyond simple resource scarcity. In high-income countries with large variations, the problem appears to be inconsistent implementation—some hospitals use these treatments routinely while others don't, even though they have the same access to medications and training opportunities. In middle-income countries, barriers may include cost, supply chain challenges, or lack of awareness among healthcare providers.

What makes this particularly concerning is that preterm birth complications can have lifelong consequences. Cerebral palsy affects movement, posture, and coordination throughout a person's life. Respiratory complications in newborns can lead to chronic lung disease, developmental delays, and repeated hospitalizations. These aren't minor health issues—they're conditions that reshape a child's entire trajectory.

What's the Path Forward?

The researchers emphasize that the solution isn't discovering new treatments or waiting for more evidence. The medications work. The challenge is implementation—getting them to every pregnant woman who needs them, regardless of where she lives. "The bigger-picture goal should now be to ensure that no matter where a baby is born, their mother has access to the evidence-based treatments that offer the best start in life," Edwards explained.

For expectant parents, this research underscores the importance of prenatal care and communication with healthcare providers. If you're at risk of preterm delivery, ask your doctor explicitly whether you're receiving both magnesium sulfate and prenatal steroids. For policymakers and hospital administrators, the message is clear: proven treatments exist, and the time to implement them universally is now.